Loading
A phase 2 trial of Samarium-153 lexidronam and Sargramostim in Prostate cancer, run by National Cancer Institute (NCI), completed.
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer is a phase 2 interventional study registered as NCT00450619 by National Cancer Institute (NCI), with 44 participants recorded, started 2007-02 and reaching its primary completion in 2012-11. Interventions recorded: Samarium Sm 153 lexidronam pentasodium, Sargramostim, Recombinant vaccinia-TRICOM vaccine, Recombinant fowlpox-TRICOM vaccine. Conditions recorded: Prostate Cancer.
Linked to the drug Samarium-153 lexidronam because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
44 enrolled.
95% CI 1.3 to 2.3; Figures from the ClinicalTrials.gov results section (first posted 2013-07-01), not from a publication · 95% CI 2.4 to 4.7
Source95% CI 3.5 to 13.3; Figures from the ClinicalTrials.gov results section (first posted 2013-07-01), not from a publication · 95% CI 5.0 to 12.6
SourceShares Samarium-153 lexidronam, Prostate cancer and the tag pipeline.
Shares Samarium-153 lexidronam and the tag pipeline.
Shares Sargramostim and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.